The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 62 | — | 20.1x | Near average | |
Growth | 78 | 25.7% | 5.6% | Above average | |
Quality | 68 | -7.0% | 7.6% | Above average | |
Safety | 50 | -21.0x | 0.4x | Near average | |
Capital Return | 24 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Akebia Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Akebia Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Akebia Therapeutics stock shows a state of complete stability in analyst estimates over the past 30 days, as the consensus price target settled at $4 with full agreement from 3 analysts. This alignment (the absence of dispersion between the low and high targets) reflects unified confidence in the stock's fair value, despite the significant gap between the current price ($1.02) and the target, suggesting expectations for strong future growth exceeding 290%.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.